ArticleThe FEBS journal2026
Structural and functional characterization of an active site-influencing variant (IMP-1-F218Y) in IMP-1 metallo-β-lactamase.
Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Antimicrobial resistance (AMR) has become a critical global health challenge, largely driven by metallo-β-lactamase (MBL)-mediated hydrolysis of β-lactam antibiotics, which remain the cornerstone of modern antimicrobial therapy. IMP-1, an MBL first identified in Japan, exhibits potent carbapenemase activity and currently lacks effective clinical inhibitors. To explore how distal mutations modulate catalytic behaviour in B1 MBLs, we characterised IMP-1 and its variant IMP-1-F218Y, using biophysical, biochemical, and structural approaches. Circular-dichroism spectra confirmed the preservation of the α-helical MBL fold in both enzymes, while kinetic analyses revealed enhanced hydrolysis by IMP-1-F218Y across most β-lactam substrates. Antimicrobial susceptibility-testing supported this observation, linking the increased catalytic efficiency of the mutant to elevated resistance, except under Zinc(II)-limiting conditions. The crystal structure of IMP-1-F218Y (2.9 Å; PDB ID: 8ZTB) showed an additional Y218-S262 hydrogen bond that reduces the active-site volume and stabilises the L3 loop, positioning W64 flatter across the catalytic cleft. Molecular-dynamics simulations captured this conformational compaction, indicating a more compact and catalytically favourable active site. Unlike natural IMP variants with selective substrate profiles, IMP-1-F218Y displayed an expanded substrate spectrum, demonstrating that a single distal substitution can modulate enzymatic plasticity and broaden catalytic range. These findings provide mechanistic insight into the structural adaptability of B1 MBLs and emphasise the importance of targeting such flexibility in the design of next-generation β-lactamase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.